Bristol-Myers Squibb Company (BMY)

Days of sales outstanding (DSO)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Receivables turnover		4.49	4.30	4.07	4.36	4.12	4.36	4.47	4.56	4.67	4.86	5.21	5.52	4.95	4.92	4.92	4.94	5.00	4.89	4.44	3.74
DSO	days	81.21	84.84	89.65	83.74	88.57	83.70	81.68	80.04	78.17	75.07	70.10	66.15	73.72	74.22	74.15	73.84	72.98	74.70	82.24	97.59

December 31, 2024 calculation

DSO = 365 ÷ Receivables turnover
= 365 ÷ 4.49
= 81.21

The days of sales outstanding (DSO) for Bristol-Myers Squibb Company have displayed fluctuation over the given period. The trend indicates a slight increase from March 31, 2020, to June 30, 2020, followed by a downward trend until March 31, 2021. Subsequently, there was marginal variability in DSO values until June 30, 2022. From September 30, 2022, to December 31, 2024, DSO showed an overall increasing pattern, with some intermittent decreases.

On average, the DSO metric for Bristol-Myers Squibb Company during the analyzed period ranged from around 66 to 89 days. A lower DSO signifies that the company collects its accounts receivable more efficiently, converting sales into cash quickly. Conversely, a higher DSO indicates a lengthy collection period, which could be a concern as it ties up capital that could otherwise be reinvested in the business.

The company's management should closely monitor the DSO metric to ensure efficient accounts receivable management and timely cash flow. Trend analysis and comparison with industry benchmarks can provide valuable insights into the company's liquidity position and operational efficiency.